β-Defensins: Linking innate and adaptive immunity through dendritic and T cell CCR6

Science

Volumn 286, Issue 5439, 1999, Pages 525-528

  Yang, D ^a   Chertov, O ^b   Bykovskaia, S N ^c   Chen, Q ^a   Buffo, M J ^c   Shogan, J ^c   Anderson, M ^d   Schroder J M ^e   Wang, J M ^a   Howard, O M Z ^b   Oppenheim, J J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d Magainin Research Institute   (United States)

^e UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; DEFENSIN; PERTUSSIS TOXIN;

ARTICLE; CHEMOTAXIS; DENDRITIC CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; LIGAND BINDING; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

ANTIBODIES; BETA-DEFENSINS; BINDING, COMPETITIVE; CELL LINE; CHEMOKINES, CC; CHEMOTAXIS; CHEMOTAXIS, LEUKOCYTE; DEFENSINS; DENDRITIC CELLS; HUMANS; IMMUNITY, ACTIVE; IMMUNITY, NATURAL; IMMUNOLOGIC MEMORY; MACROPHAGE INFLAMMATORY PROTEINS; PERTUSSIS TOXIN; PROTEINS; RECEPTORS, CHEMOKINE; RECOMBINANT PROTEINS; T-LYMPHOCYTE SUBSETS; TRANSFECTION; VIRULENCE FACTORS, BORDETELLA;

EID: 0033569408     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.286.5439.525     Document Type: Article

References (32)

1. T. Ganz and R. I. Lehrer, Curr. Opin. Immunol. 64, 584 (1994).
2. E. D. Stolzenberg, C. M. Anderson, M. R. Ackermann, R. H. Whitlock, M. Zasloff, Proc. Natl. Acad. Sci. U.S.A. 94, 8686 (1997).
3. P. Fehlbaum et al., J. Biol. Chem. 269, 33159 (1994).
4. W. F. Broekaert, F. R. G. Terras, B. P. A. Cammue, R. W. Osborn, Plant Physiol. 108, 1353 (1995).
5. G. Diamond, J. P. Russell, C. L. Bevins, Proc. Natl. Acad. Sci. U.S.A. 93, 5156 (1996).
6. J. Harder, J. Bartels, E. Christophers, J. M. Schröder, Nature 387, 861 (1997).
7. K. W. Bensch, M. Raida, H. J. Magert, P. S. Knappe, W. G. Forssmann, FEBS Lett. 368, 331 (1995).
8. J. J. Smith, S. M. Travis, E. P. Greenberg, M. J. Welsh, Cell 85, 229 (1996).
9. M. Goldman et al., ibid. 88, 553 (1997).
10. O. Chertov et al., J. Biol. Chem. 271, 2935 (1996).
11. J. W. Lillard, P. N. Boyaka, O. Chertov, J. J. Oppenheim, J. R. McGhee, Proc. Natl. Acad. Sci. U.S.A. 96, 651 (1999).
12. Z. Prohaszka et al., Mol. Immunol. 34, 809 (1997).
13. 125I-LARC with a specific radioactivity of 2000 Ci/mmol was purchased from Amersham Life Science (Cleveland, OH).
14. 7 U/mg) (Pepro Tech) to induce maturation if required.
15. M. C. Dieu et al., J. Exp. Med. 188, 374 (1998).
16. 3, at pH 7.4)]. Subsequently, the cells were directly stained with fluorescein isothiocyanate-or phycoerythrin-conjugated mouse monoclonal antibodies to CD83 (Immunotech, Marseille, France), CD1a, CD86, HLA-DR (PharMingen, San Diego, CA), or CCR6 (R&D Systems) at 24°C for 1 hour at a final concentration of 5 μg/ml in FACS buffer. As a negative control, DCs were stained with isotype-matched irrelevant antibodies. Thereafter, the cells were washed twice with FACS buffer and twice with PBS, resuspended in PBS containing 1% paraformaldehyde, and analyzed with a flow cytometer (Coulter or FACScan Epics Analyzer).
17. J. Banchereau and R. M. Steinman, Nature 392, 245 (1998).
18. D. Yang et al., unpublished observations.
19. B. J. Rollins, Blood 90, 909 (1997); P. M. Murphy, Cytokine Growth Factor Rev. 7, 47 (1996).
20. B. J. Rollins, Blood 90, 909 (1997); P. M. Murphy, Cytokine Growth Factor Rev. 7, 47 (1996).
21. A. Granelli-Piperno et al., J. Exp. Med. 184, 2433 (1996).
22. L. L. Xu, M. K. Warren, W. L. Rose, W. H. Gong, J. M. Wang, J. Leukocyte Biol. 60, 365 (1996).
23. D. R. Greaves et al., J. Exp. Med. 186, 837 (1997).
24. H. Ueda et al., J. Biol. Chem. 272, 24966 (1997).
25. A. Ben-Baruch et al., ibid. 270, 22123 (1995).
26. C. J. Raport, J. Gosling, V. L. Schweickart, P. W. Gray, I. F. Charo, ibid. 271, 17161 (1996).
27. Parental HEK293 epithelial cells were transfected with linearized CCR6 mammalian expression constructs by electroporation. After selection in Dulbecco's minimum essential medium (Biowhittaker), 10% FBS, 2 mM glutamine, penicillin (100 U/ml), and streptomycin (100 μg/ml) containing G418 (400 μg/ ml) (Life Technologies, Gaithersburg, MD) for 2 weeks, single-cell cloning was performed. The expression of functional CCR6 was confirmed by saturation binding, FACS analysis of surface CCR6, and chemotaxis of the transfectant cells in response to LARC.
28. T. Hiratsuka et al., Biochem. Biophys. Res. Commun. 249, 943 (1998).
29. Data available at www.sciencemag.org/feature/data/ 1042876.shl.
30. A. Albini et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13153 (1998); D. Weissman et al., Nature 389, 981 (1997).
31. A. Albini et al., Proc. Natl. Acad. Sci. U.S.A. 95, 13153 (1998); D. Weissman et al., Nature 389, 981 (1997).
32. We thank P. W. Gray and M. Tsang for human CCR6 expression constructs and antibody to CCR5, respectively; N. Dunlop for technical assistance; and C. Fogle and C. Nolan for secretarial assistance. Supported in part by a fellowship from the Office of International Affairs of the National Cancer Institute (NCI) of NIH (to D.Y.) and by contract N01-CO-56000 from NCI of NIH (to O.C. and O.M.Z.H). The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. government.